Marc Tessier-Lavigne

CIK 1437435 · EVP, RESEARCH DRUG DISCOVERY · last filed 2025-06-05

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$44.07M

Companies

6

Total Filings

62

Lifetime Open-Market Net

-$93.00M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DNLI Director 1,965,424 $21.66 $42.57M -$36.87M 25 2025-06-05
REGN Director 2,434 $612.14 $1.49M -$54.63M 25 2023-01-05
AGIO Director $29.46 $0 3 2016-06-23
Juno Therapeutics, Inc. (JUNO) Delisted Director 250,000 $0 3 2016-06-21
PFE Director $26.21 $0 4 2015-04-24
DNA EVP, RESEARCH DRUG DISCOVERY 1,159 $7.89 $9.1K -$1.50M 1 2008-07-18

Recent Filings · Page 2 of 7

62 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2022-07-27 DNLI Sell (S) −20,000 -$712.1K EDGAR
2022-06-28 DNLI Sell (S) −20,000 -$676.6K EDGAR
2022-06-27 DNLI Disp (D) −60,000 -$1.84M EDGAR
2022-06-06 DNLI Grant (A) +5,986 $0 EDGAR
2022-03-25 DNLI Sell (S) −20,000 -$676.6K EDGAR
2022-03-23 REGN Mixed -$2.30M EDGAR
2022-03-18 REGN Mixed -$3.69M EDGAR
2022-01-05 REGN Grant (A) +191 $0 EDGAR
2021-12-30 DNLI Mixed −63,131 -$2.81M EDGAR
2021-12-10 REGN Mixed -$1.11M EDGAR
Showing 1120 of 62
Page 2 of 7
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.